VivoSeq
Other

Central Precocious Puberty

14

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Central precocious puberty is an emerging landscape with 14 programs across 10 companies. The most active players are Ipsen, Foresee Pharmaceuticals Co., Ltd., Eastern Cooperative Oncology Group. 5 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

75/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

1 program

Phase 3F

Foresee Pharmaceuticals Co., Ltd.

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

ApprovedH

HanAll BioPharma Co., Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed14 · 82%
Active, not recruiting2 · 12%
Unknown status1 · 6%

Clinical Trials

Trial Activity

17 trials

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Active, not recruiting·FForesee Pharmaceuticals Co., Ltd.·Phase 3·NCT05493709·93 enrolled
LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty
Active, not recruiting·DDebiopharm International SA·Phase 3·NCT06129539·56 enrolled
Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
Completed·Ipsen logoIpsen·Phase 3·NCT04736602·32 enrolled
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
Completed·Takeda logoTakeda·Phase 4·NCT05341115·80 enrolled
Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine
Completed·—·Phase 4·NCT03963752·126 enrolled
A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
Completed·Takeda logoTakeda·N/A·NCT02993926·108 enrolled
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Completed·DDebiopharm International SA·Phase 3·NCT01467882·44 enrolled
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
Completed·Takeda logoTakeda·Phase 4·NCT02427958·307 enrolled
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
Completed·AbbVie logoAbbVie·Phase 3·NCT00667446·72 enrolled
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Completed·AbbVie logoAbbVie·Phase 3·NCT03695237·45 enrolled
Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty
Completed·—·Phase 4·NCT03316482·58 enrolled
Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT00779103·36 enrolled
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Completed·AAbbott·Phase 3·NCT00635817·84 enrolled
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
Completed·Ipsen logoIpsen·Phase 3·NCT05029622·66 enrolled
Study of Lupron Depot In The Treatment of Central Precocious Puberty
Completed·AAbbott·Phase 3·NCT00660010·55 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)